Carmat: capital increase completed
The medical technology company plans to use these funds to strengthen its equity and finance its short-term working capital, and in particular to pursue the development of its production and sales, as well as its EFICAS clinical trial in France.
Following the offer, Carmat's 12-month financing requirement is around €50 million (with a financial horizon of end-February 2024), which could be reduced to €35 million (with a financial horizon of mid-May 2024) in the event of a definitive agreement with the EIB.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction